Get the Stockscreener App
64.34
0.24%
0.155
After Hours:
64.31
-0.03
-0.05%
Biomarin Pharmaceutical Inc stock is traded at $64.34, with a volume of 1.11M.
It is up +0.24% in the last 24 hours and down -4.07% over the past month.
See More
Previous Close:
$64.19
Open:
$64.19
24h Volume:
1.11M
Relative Volume:
0.75
Market Cap:
$12.70B
Revenue:
$2.75B
Net Income/Loss:
$322.29M
P/E Ratio:
38.53
EPS:
1.67
Net Cash Flow:
$300.88M
1W Performance:
+0.72%
1M Performance:
-4.07%
6M Performance:
-25.94%
1Y Performance:
-28.35%
1-Day Range:
$63.87
$64.71
1-Week Range:
$61.71
$64.71
52-Week Range:
$60.63
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
64.34 | 12.70B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
Robeco Institutional Asset Management B.V. Sells 124,092 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
3 Reasons Growth Investors Will Love BioMarin (BMRN) - Yahoo Finance Australia
BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET - Marketscreener.com
BioMarin Earnings Call: CEO Alexander Hardy to Present Strategic Vision & 2024 Results - StockTitan
Prediction: This Pharma Stock Will Be the Best Performer in 2025 - 24/7 Wall St.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by abrdn plc - MarketBeat
Zacks.com featured highlights BioMarin, Cheesecake Factory, Leidos and The Ensign - Yahoo Finance
18,939 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Acquired by Mediolanum International Funds Ltd - MarketBeat
Level Wealth Management LLC Invests $627,000 in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Swedbank AB Has $28.40 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BofA Adjusts Price Target on BioMarin Pharmaceutical to $99 From $100 -February 03, 2025 at 10:27 am EST - Marketscreener.com
Top 10 Takeover Targets of 2025 - Genetic Engineering & Biotechnology News
Is BioMarin Pharmaceutical (BMRN) the Best Depressed Stock to Invest in Now? - Insider Monkey
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now? - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Atomi Financial Group Inc. - Defense World
12 Best Depressed Stocks to Invest in Now - Insider Monkey
Merit Financial Group LLC Invests $317,000 in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy - Seeking Alpha
BioMarin turns to ex-Roche dealmaker James Sabry to build ‘next version’ of 27-year-old company - Endpoints News
Why Is Andreas Halvorsen Bullish On BioMarin Pharmaceutical Inc. (BMRN) Now? - Yahoo Finance
Zacks.com featured highlights include BioMarin, Amazon.com, Leidos and The Ensign - Yahoo Finance
Brokers Offer Predictions for BMRN FY2025 Earnings - Defense World
Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks - Insider Monkey
Cantor Fitzgerald Predicts BMRN FY2025 Earnings - MarketBeat
Fort Washington Investment Advisors Inc. OH Sells 12,170 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Sabry Lays Out BioMarin’s New Business Development Plan - News & Insights
Earnings are growing at BioMarin Pharmaceutical (NASDAQ:BMRN) but shareholders still don't like its prospects - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025 - Insider Monkey
Here is Why Growth Investors Should Buy BioMarin (BMRN) Now - Yahoo Finance
10 Under-the-Radar Stocks with Massive Upside for 2025 - Insider Monkey
Avanza Fonder AB Takes Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Head to Head Comparison: BioMarin Pharmaceutical (NASDAQ:BMRN) and Acura Pharmaceuticals (OTCMKTS:ACUR) - Defense World
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Sees Large Decrease in Short Interest - MarketBeat
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Down 3%Should You Sell? - MarketBeat
BioMarin Pharmaceutical Target of Unusually High Options Trading (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Sees Unusually Large Options Volume (NASDAQ:BMRN) - Defense World
BioMarin stock touches 52-week low at $60.77 amid challenges - MSN
BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 1-Year LowShould You Sell? - MarketBeat
BioMarin files UPC’s first pharma infringement suit in over three months - IAM
Are BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - Simply Wall St
Assenagon Asset Management S.A. Grows Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Wedmont Private Capital Makes New $430,000 Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Down 3%What's Next? - MarketBeat
UTHR: 3 Niche Biotech Stocks Redefining Innovation - StockNews.com
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
5 Biotech Stocks Worth Adding to Your Portfolio in 2025 - Yahoo Finance
Goldman Sachs maintains Buy on BioMarin shares - Investing.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $94.20 Consensus Target Price from Analysts - MarketBeat
BioMarin sues Ascendis Pharma over patent infringement By Investing.com - Investing.com Canada
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):